Assessing the Effectiveness and Safety of Erythropoietin in Chronic Kidney Disease: An Observational Study

End-Stage Renal Disease (ESRD) often leads to anemia, contributing to a spectrum of complications, from lethargy to heightened vulnerability to infections. This study explores the potential of correcting anemia and reducing reliance on blood transfusions in ESRD patients with the administration of subcutaneous erythropoietin (4000 IU thrice a week). The primary objectives were to evaluate the effectiveness, side-effects, and the diminished need for blood transfusions following erythropoietin (EPO) administration in subjects undergoing Maintenance hemodialysis for ESRD. Sixty subjects aged >18 years, receiving EPO, were enrolled in this study for a duration of 6 months. Primary end points, including Hemoglobin (Hb), Serum Ferritin, Total Iron Binding Capacity (TIBC), and Serum Iron, along with side-effects of EPOETIN ALPHA, were assessed over a 12week epoetin therapy period. After 12 weeks, notable improvements were observed, including a 13.86% increase in Hb, a 32.84% increase in serum iron, a 5.67% decrease in TIBC, and a 3.93% decrease in serum ferritin. Mild side-effects were encountered by 28 out of 60 subjects. A substantial 75% reduction in blood transfusion frequency was noted. The study concludes that EPO demonstrated efficacy with manageable adverse reactions, significantly reducing the need for blood transfusions. Thus, suggesting a positive impact on the anemic status of subjects undergoing maintenance hemodialysis for ESRD.